Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$3.60MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ryan J. Watts
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 503
- Beta
- 1.00
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.32
Financials
Revenue
$3.60M+462.2%Net Income
$-127.55MEBITDA
$-123.98MFree Cash Flow
$-97.81MEPS (diluted)
$-0.68Shares Outstanding (diluted)
187.31M+2657.0%Operating Expenses
$133.30MCash & Debt
$710.47MReturn of Capital
$0.00Revenue by Segment (annual)
$3.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-512.54M | $-2.97 |
| 2024 | $0.00 | $-422.77M | $-2.57 |
| 2023 | $330.53M | $-145.22M | $-1.06 |
| 2022 | $108.46M | $-325.99M | $-2.60 |
| 2021 | $48.66M | $-290.58M | $-2.39 |
| 2020 | $335.66M | $71.14M | $0.65 |
| 2019 | $26.68M | $-197.61M | $-2.07 |
| 2018 | $129.16M | $-36.24M | $-0.39 |
| 2017 | $0.00 | $-88.19M | $-5.89 |
| 2016 | $0.00 | $-86.65M | $-13.49 |
| 2015 | $0.00 | $-16.79M | $-5.58 |
Valuation
DNLIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·21d ago·Positive
Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·46d ago·Positive
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
View source ↗ - Newsseekingalpha.com·48d ago·Positive
Denali Therapeutics: Bullish On Avlayah And Their Prospects AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a credible launch ramp. However, AVLAYAH's US label limits its near-term potential. Zafinofusp alfa and four TV-enabled 2027 readouts provide meaningful pipeline upside beyond AVLAYAH.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodege…
View source ↗ - Newsgurufocus.com·56d ago·Negative
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Denali Therapeutics Inc (NASDAQ: DNLI) at a traded price of $25.7
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.37 per share
Typical surprise +2.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.68 vs $-0.51miss
- Thu, May 7$-0.69 vs $-0.73beat
- Thu, Feb 26$-0.73 vs $-0.75beat
- Thu, Nov 6$-0.74 vs $-0.76beat
- Mon, Aug 11$-0.72 vs $-0.74beat
- Tue, May 6$-0.78 vs $-0.71miss
Estimates and results for DNLI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DNLI officers and directors.
- Bought
- $23k
- Sold
- $10.9m
2 trades
20 trades
- Chin Peter Scottsold
- Thornberry Nancysold
- Thornberry Nancysold
- Schuth Alexander O.sold
- Schuth Alexander O.sold
- Watts Ryan J.sold
- Schuth Alexander O.sold
- Baker Bros. Advisors Lpbought
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DNLI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.